PTC Therapeutics, Inc.
PTCT Real Time Price USDRecent trades of PTCT by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in PTCT holdings by institutional investors
Quarterly net insider trading by PTCT's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$170,000 Oct 20, 2026 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$170,000 Jul 20, 2026 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$390,000 Apr 20, 2026 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Trade (domestic/foreign)
-
$140,000 Jan 20, 2026 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$140,000 Oct 20, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$120,000 Jul 21, 2025 Issue: Taxation/Internal Revenue Code Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$210,000 Apr 21, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$80,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$90,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$90,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$500,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$170,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations
-
$170,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code Budget/Appropriations
-
$190,000 Feb 04, 2025 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$570,000 Feb 04, 2025 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid Taxation/Internal Revenue Code
-
$160,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$190,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$200,000 Jul 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$370,000 Apr 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$190,000 Apr 20, 2022 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$180,000 Oct 20, 2021 Issue: None
-
$180,000 Jul 20, 2021 Issue: None
-
$180,000 Apr 20, 2021 Issue: None
-
$180,000 Jan 21, 2021 Issue: None
-
$180,000 Oct 29, 2020 Issue: None
-
$50,000 Jul 20, 2020 Issue: Health Issues
-
$50,000 Apr 26, 2020 Issue: Health Issues
-
$50,000 Feb 25, 2020 Issue: Health Issues
-
$20,000 Apr 17, 2019 Issue: Budget/Appropriations
-
$40,000 Apr 17, 2019 Issue: Budget/Appropriations
-
$30,000 Jan 22, 2019 Issue: Budget/Appropriations
-
$60,000 Jan 22, 2019 Issue: Budget/Appropriations
-
$10,000 Jan 16, 2019 Issue: None
-
$10,000 Oct 18, 2018 Issue: Health Issues Medicare/Medicaid
-
$30,000 Oct 18, 2018 Issue: Budget/Appropriations
-
$60,000 Oct 18, 2018 Issue: Budget/Appropriations
-
$30,000 Jul 20, 2018 Issue: Budget/Appropriations
-
$60,000 Jul 20, 2018 Issue: Budget/Appropriations
-
$30,000 Apr 20, 2018 Issue: Budget/Appropriations
-
$30,000 Apr 20, 2018 Issue: Budget/Appropriations
-
$30,000 Jan 17, 2018 Issue: Budget/Appropriations
-
$30,000 Jan 17, 2018 Issue: Budget/Appropriations
-
$30,000 Oct 18, 2017 Issue: Budget/Appropriations
-
$30,000 Oct 18, 2017 Issue: Budget/Appropriations
-
$30,000 Aug 09, 2017 Issue: Budget/Appropriations
-
$30,000 Aug 09, 2017 Issue: Budget/Appropriations
-
$30,000 Jul 18, 2017 Issue: Budget/Appropriations
-
$10,000 Apr 20, 2017 Issue: Health Issues
-
$30,000 Apr 19, 2017 Issue: Budget/Appropriations
-
$10,000 Jan 19, 2017 Issue: Budget/Appropriations
-
$30,000 Jan 12, 2017 Issue: Budget/Appropriations
-
$30,000 Oct 20, 2016 Issue: Health Issues
Former government officials who have lobbied for PTCT
23 former government officials from 17 congressional offices at 6 lobbying firms have lobbied for PTCT, most recently Oct 20, 2026.
-
Remy Mason Senate Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz -
John Stone House Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C
-
Brent Del Monte Other See prior filing
-
Robb Walton Senate Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes -
Daniel Farmer House Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space -
Joel Bailey House COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. Rahall -
Alanna Temme House Legislative Director, U.S. Representative Jon Porter -
Sophie Khanahmadi House Legislative Asst., Rep. Martha Roby; Legislative Asst., Rep. Lee Terry; Staff Asst./LC, Senator Jeff Sessions
PTCT Estimated quarterly lobbying spending
PTCT Revenue by Segment or Geography
New PTCT patent grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded to PTCT from public contracts
Recent insights relating to PTCT
Recent picks made for PTCT stock on CNBC
ETFs with the largest estimated holdings in PTCT
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $PTCT stock a Buy, Sell, or Hold?
- What is the price target for $PTCT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $PTCT stock?
- Who owns the most shares of $PTCT stock?
- What funds own $PTCT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view PTCT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
- Address Warren, NJ
- Market Cap 5.1 billion
- Employees 991
- Industrial Classification Pharmaceutical Preparations
PTC Therapeutics, Inc. (PTCT) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for PTC Therapeutics, Inc. (PTCT).
Quiver Premium charts PTCT's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at PTCT, per a recent SEC DEF 14A filing. We estimate that the median employee at PTC THERAPEUTICS, INC. is paid $220,097.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|